Early pregnancy loss and miscarriage — the AU general-practice approach

The GP’s role in early pregnancy loss

Approximately 15–20% of all clinically recognised pregnancies end in miscarriage — one of the most common events in reproductive medicine and one of the most emotionally significant presentations a GP encounters. Most losses occur before 12 weeks and most are caused by chromosomal variation in the embryo rather than anything the patient did or could have avoided. The GP’s role spans four essential tasks: excluding ectopic pregnancy (the most urgent clinical priority), confirming pregnancy location and viability with serial serum β-hCG and transvaginal ultrasound, offering management options with genuine shared decision-making, and providing compassionate bereavement care from the first consultation onward.

RANZCOG and Therapeutic Guidelines both emphasise that these tasks are simultaneous — the emotional care is not deferred until the clinical pathway is complete.

A. Core clinical — the AU general-practice framework

Definitions and epidemiology

In Australia, a miscarriage is defined as pregnancy loss before 20 weeks gestation. After 20 weeks, loss is classified as stillbirth and involves the perinatal team. Approximately 80% of miscarriages occur before 12 weeks; the rate rises sharply with maternal age — roughly 10% at ages 25–29, 20% at 35, 40% at 40, and over 80% at 45. Biochemical pregnancy (positive β-hCG without confirmed intrauterine pregnancy on ultrasound) accounts for an additional 30% of conceptions and is not always clinically apparent. Recurrent pregnancy loss (RPL) is defined by ESHRE 2023 and RANZCOG as two or more consecutive losses.

Excluding ectopic pregnancy

Ectopic pregnancy is the leading cause of first-trimester maternal death in Australia. Every woman presenting with early pregnancy and bleeding or pain must be assessed with ectopic pregnancy as the working diagnosis until excluded. Risk factors include a prior ectopic pregnancy, pelvic inflammatory disease, tubal surgery, an IUD in situ, IVF (particularly with a heterotopic risk), endometriosis, smoking, and age over 35.

The NICE NG126 and RANZCOG diagnostic pathway uses:

• Quantitative serum β-hCG — a normal intrauterine pregnancy rises by at least 53% in 48 hours; sub-optimal rise or plateau suggests ectopic or failing pregnancy. The discriminatory zone — above which an intrauterine pregnancy should be visible on transvaginal ultrasound — is approximately 1,500 IU/L.
• Transvaginal ultrasound — an intrauterine pregnancy is typically visible from 4½–5 weeks; the yolk sac from 5–5½ weeks; fetal cardiac activity from 6 weeks. Adnexal mass, free fluid in the pouch of Douglas, a “tubal ring sign”, or absence of intrauterine pregnancy above the discriminatory zone all suggest ectopic.
• Haemodynamic instability — sudden severe pain, shoulder-tip pain (referred from diaphragmatic irritation), faintness, or hypotension indicate a ruptured ectopic and require immediate ambulance transfer for emergency surgery.

Clinical types of miscarriage

Type	Cervix	β-hCG	Bleeding	Ultrasound	Management
Threatened	Closed	Appropriate rise	Light	Viable IUP	Reassure; repeat ultrasound at 7–14 days
Inevitable	Open	Positive	Moderate–heavy	IUP, may be non-viable	Expectant, medical, or surgical
Incomplete	Open	Positive, falling	Heavy with tissue	Retained products	Medical or surgical
Missed	Closed	Plateau	Nil or minimal	No cardiac activity or empty sac ≥25 mm	Confirm on repeat ultrasound if borderline; then manage
Complete	Closed	Falling rapidly	Settling	Empty uterus	Reassure; safety-net; β-hCG to zero
Septic	Open	Positive	Offensive discharge, fever	Retained products	Urgent evacuation + IV antibiotics
Ectopic	Closed	Suboptimal rise	Spotting + pain	No IUP; adnexal mass	Urgent ED transfer

Management options

Therapeutic Guidelines and RANZCOG support three well-established approaches; the choice is made through informed shared decision-making:

Expectant management — waiting for the pregnancy to pass naturally. Successful in approximately 50–70% of incomplete miscarriages and 30–50% of missed miscarriages within two weeks. Suitable when the patient is haemodynamically stable, there is no sign of infection, and she is willing and able to monitor at home. Written safety-net advice is essential: return to ED if bleeding exceeds two pads per hour for two hours, fever develops, or pain is severe or unremitting.

Medical management — misoprostol — misoprostol 800 µg administered vaginally is the standard medical approach for missed or incomplete miscarriage. A repeat dose at 48 hours if no bleeding has occurred increases efficacy. Per NICE NG126, pre-treatment with mifepristone 200 mg orally 24–48 hours before misoprostol (the MIFEMISO protocol) reduces the need for surgical intervention. Misoprostol is PBS Authority Required (Streamlined) for this indication. Australian Medicines Handbook guidance covers expected side effects: cramping, bleeding, nausea, diarrhoea, and transient fever. Adequate analgesia (scheduled ibuprofen plus paracetamol, with oral codeine as rescue) and a 24-hour contact pathway are essential.

Surgical management — suction curettage — MBS items 35630–35636, performed by a gynaecologist as a day-stay procedure. Indicated for heavy or ongoing bleeding, septic miscarriage, patient preference, or failed expectant or medical management. Risks include anaesthesia, uterine perforation (~1%), infection, and (rarely) intrauterine adhesion formation (Asherman syndrome) with repeated procedures.

Anti-D immunoglobulin

Per Australian Red Cross Lifeblood and NHMRC guidelines: all Rh-negative women undergoing miscarriage, ectopic pregnancy management, termination of pregnancy, or significant antepartum bleeding should receive anti-D immunoglobulin to prevent Rh alloimmunisation — an antibody response that can threaten future Rh-positive pregnancies with haemolytic disease of the foetus and newborn.

• Under 12 weeks gestation: 250 IU IM (check blood group + antibody screen first).
• 12 weeks or more: 625 IU IM.

Document the batch number and confirm blood group before administration. Anti-D is provided at no cost through the National Blood Authority and Australian Red Cross Lifeblood. It does not appear on the PBS.

Follow-up after miscarriage

Confirm completion with serial β-hCG to zero (weekly until <5 IU/L) or ultrasound showing empty uterus. Screen for perinatal anxiety and depression using the Edinburgh Postnatal Depression Scale (EPDS) at 2 weeks and 6 weeks post-loss. Most patients can conceive in the next ovulatory cycle; there is no medical requirement to wait beyond physical recovery. Pre-conception counselling — folate 0.4 mg daily (5 mg daily if high-risk), iodine 150 µg, thyroid function, and lifestyle optimisation — is appropriate at the follow-up visit.

B. Evidence appraisal — what works in early pregnancy loss

Intervention	Direction	Evidence quality	Notes
Misoprostol 800 µg PV for missed miscarriage	For	🟢	MIST and MIFEMISO trials; effective, patient-centred
Mifepristone pre-treatment + misoprostol	For	🟢	MIFEMISO 2020 — reduces need for surgery (RR reduction 17%); endorsed NICE
Anti-D for Rh-negative women	For	🟢	Consensus; prevents alloimmunisation in future pregnancies
Aspirin + LMWH in antiphospholipid syndrome	For	🟢	Live birth rate ~70–80% vs <30% untreated
Levothyroxine for subclinical hypothyroidism with TPO antibodies	For	🟢	Reduces miscarriage risk; treat to TSH <2.5 pre-conception
Hysteroscopic septum resection	For	🟡	Cohort data; TRUST trial inconclusive but RANZCOG supports if symptomatic
Progesterone for RPL with bleeding in next pregnancy	For	🟢	PRISM 2019 — NNT ~14 in subgroup with bleeding + prior loss; 400 mg PV BD to 16 weeks
Expectant care / EPAU support	For	🟡	Improved psychological outcomes; possible live-birth signal
Routine inherited thrombophilia screen in RPL	Against	🔴	ESHRE 2023 — low yield; LMWH trials (ALIFE, ALIFE2, SPIN) showed no live-birth benefit
IVIG / intralipid / immunotherapy	Against	🔴	No clear benefit; costly; outside research protocol
Empirical progesterone for all RPL (no bleeding)	Equivocal	🟡	PROMISE trial null in unselected RPL
Bed rest for threatened miscarriage	Against	🔴	No evidence of benefit; possible VTE risk

C. Recurrent pregnancy loss — the targeted workup

Approximately 1–2% of couples experience RPL. Investigations follow ESHRE 2023 and RANZCOG guidance after two or more consecutive losses:

Recommended investigations:

• Antiphospholipid antibodies × 2 (12 weeks apart): lupus anticoagulant, anti-cardiolipin IgG and IgM, anti-β2-glycoprotein I — the most clinically actionable finding.
• TSH, free T4, and thyroid peroxidase antibodies — autoimmune thyroid disease is treatable.
• Fasting glucose and HbA1c — poorly controlled diabetes is a modifiable risk.
• Pelvic 3D ultrasound ± hysteroscopy or hysterosalpingogram — septate uterus is surgically correctable.
• Parental karyotype (particularly after three or more losses, or if products-of-conception cytogenetics are abnormal) — detects balanced translocations in 2–5%.
• Products-of-conception chromosomal microarray — distinguishes embryonic from maternal aetiology and avoids unnecessary workup.

Not recommended routinely:

• Inherited thrombophilia panel (factor V Leiden, prothrombin mutation) — LMWH does not improve live birth rate in the absence of antiphospholipid syndrome.
• NK cell counts, cytokine panels — no evidence base; not recommended by ESHRE.
• Empirical IVIG, intralipid, or corticosteroids outside clinical trials.

Management of confirmed antiphospholipid syndrome: aspirin 100 mg daily plus low-molecular-weight heparin (enoxaparin 40 mg subcutaneously daily) from confirmation of intrauterine pregnancy through to six weeks postpartum. Refer to obstetric medicine. RANZCOG manages APS-related RPL in a specialist obstetric setting.

About half of RPL cases remain unexplained after a full workup. Supportive care — early reassurance scans, dedicated Early Pregnancy Assessment Unit follow-up, and trauma-informed communication — is associated with improved live-birth rates in cohort studies and is integral to management regardless of aetiology.

D. Australian operations

MBS items

Item	Purpose
23, 36, 44	Standard GP consultations — assessment, counselling, RPL workup
2715/2717	Mental Health Treatment Plan / review — for perinatal anxiety, depression, or grief
80000–80020	Better Access psychology — up to 10 subsidised sessions per year
55700/55706	Early pregnancy ultrasound — often bulk-billed
66719/66722	Quantitative β-hCG
66695	Blood group and antibody screen — before anti-D
35630–35636	Gynaecological surgery — D&C / suction curettage (performed by gynaecologist)
16500	Antenatal first visit — for subsequent pregnancy

PBS items

• Misoprostol 200 µg tablets — Authority Required (Streamlined) for missed or incomplete miscarriage; 4 tablets vaginally.
• Mifepristone 200 mg + misoprostol (MS-2-Step®) — Authority Required, prescriber-registered via MS Health; primarily for medical termination ≤9 weeks; off-label for some miscarriage pathways.
• Levothyroxine — General Schedule for confirmed thyroid disease.
• Aspirin 100 mg — General Schedule (also available over the counter).
• Enoxaparin (Clexane) — Authority Required in APS-related pregnancy.

Anti-D immunoglobulin is funded through the National Blood Authority — not on PBS — and is free at point of care.

Referral pathways

• Public system: Early Pregnancy Assessment Units (EPAUs) at major maternity hospitals (Royal Women’s Hospital, RPA, Mater Mothers, King Edward Memorial Hospital) provide same-day or next-day transvaginal ultrasound and serial β-hCG review; urgent referral for haemodynamic instability or suspected ectopic.
• Private: obstetrician or gynaecologist; private EPAU.
• Fertility specialist (RANZCOG-CREI): for RPL workup and management beyond GP scope, particularly after two or more losses.
• Genetic counselling: when parental karyotype identifies a balanced translocation.

Bereavement and mental-health support

Grief after miscarriage is real and significant. One in three people with RPL develop clinically significant anxiety or depression. Routine screening at every follow-up visit using the EPDS is best practice.

• PANDA Helpline 1300 726 306 — Monday to Saturday, 9am–7:30pm AEST
• SANDS Australia 1300 308 307 — 24/7 peer support
• Pink Elephants Support Network — peer-led, online, GP-recommended
• COPE — Centre of Perinatal Excellence 1300 800 117
• Gidget Foundation — telehealth perinatal psychology
• Lifeline 13 11 14 for acute distress

E. Special populations

Adolescents. Miscarriage in a young person may carry compounded emotional complexity — unplanned pregnancy, parental disclosure, school and social pressures. A trauma-informed, confidential, and non-judgmental approach is essential. Offer referral to a youth-specific counsellor and ensure the young person understands their healthcare rights and confidentiality.

ATSI Australians. Pregnancy loss in Aboriginal and Torres Strait Islander families is Sorry Business — requiring specific cultural protocols around naming, photographs, and hand or footprint mementos. Involve an Aboriginal Health Worker where available. ATSI women have higher rates of preterm birth, maternal mortality, and late access to antenatal care; early relationship-building with a continuity GP improves outcomes for subsequent pregnancies.

CALD communities. Use TIS National (131 450) for interpreter services. Respect diverse mourning rituals and food practices. Islamic communities may have specific requirements around foetal remains.

LGBTQI+ families. Same-sex couples, transgender individuals, and families formed through IVF or surrogacy face additional layers of disenfranchised grief. Affirming language and explicit acknowledgement of the loss are particularly important. Pink Elephants and PANDA both offer inclusive resources.

Workplace and legal considerations. Under current Fair Work legislation, two days of unpaid compassionate leave apply to miscarriage. Some employers offer additional paid arrangements. A medical certificate is appropriate and can be provided compassionately without unnecessary clinical detail.

When to escalate

Transfer to the emergency department immediately (ambulance if possible) for:

• Haemodynamic instability (hypotension, tachycardia, pallor, pre-syncope or syncope)
• Severe unremitting lower abdominal pain with localised tenderness
• Shoulder-tip pain (diaphragmatic irritation from intraperitoneal blood)
• Suspected ruptured ectopic pregnancy
• Fever with uterine tenderness or offensive vaginal discharge (septic miscarriage)

Same-day gynaecology referral or EPAU review for:

• Suspected ectopic pregnancy that is not immediately life-threatening
• β-hCG plateau or suboptimal rise with pregnancy of unknown location
• Heavy bleeding not settling with conservative management

Routine obstetric medicine or fertility specialist referral for:

• Confirmed antiphospholipid syndrome
• RPL with identified anatomical abnormality
• RPL after two or more losses for specialist workup coordination

What this article is and is not

This is general health information based on Australian clinical guidelines — RANZCOG, Therapeutic Guidelines, ESHRE, NICE NG126, Australian Red Cross Lifeblood anti-D guidelines, NHMRC, and COPE perinatal mental health resources. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about the management of a specific pregnancy loss, including all medication and procedural choices, are made with your own GP and treating clinicians.

For support: Pink Elephants, PANDA 1300 726 306, SANDS 1300 308 307, COPE 1300 800 117. For urgent symptoms or collapse: call triple zero (000) or go immediately to the emergency department. For consumer information: HealthDirect — Miscarriage, Better Health Channel.

---

Sources cited

1. RANZCOG — Early Pregnancy Loss Statement
2. RANZCOG — Recurrent Miscarriage
3. Therapeutic Guidelines (eTG) — Obstetrics and Gynaecology
4. Australian Medicines Handbook
5. ESHRE — Recurrent Pregnancy Loss Guideline 2023
6. NICE NG126 — Ectopic pregnancy and miscarriage
7. Australian Red Cross Lifeblood — Anti-D Guidelines
8. NHMRC — Australian Immunisation Handbook (Rh prophylaxis)
9. Centre of Perinatal Excellence (COPE) — Perinatal Mental Health Guideline
10. PANDA — Perinatal Anxiety and Depression Australia
11. Pink Elephants Support Network
12. SANDS Australia
13. HealthDirect — Miscarriage
14. Better Health Channel — Miscarriage